Utility of resistance index (RI) measured with renal doppler ultrasonography to elucidate induction therapy of Tolvaptan

Utility of resistance index (RI) measured with renal doppler ultrasonography to elucidate induction therapy of Tolvaptan - Effect of Tolvaptan using kidney resistance index

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027765

Enrollment

Registered

2017-06-20

Start date

2017-06-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis with ascites

Interventions

Tolvaptan at 3.75mg/day was administered to cirrhotic patients with ascites unresponsive to standard diuretic therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)a diagnosis of cirrhosis via laboratory data, imaging abnormalities, and the presence of a primary disease; (2) ascites caused by liver cirrhosis; and (3) unresponsive to standard diuretics such as furosemide and spironolactone.

Exclusion criteria

Exclusion criteria: (1) active gastrointestinal bleeding, (2) overt hepatic encephalopathy, (3) spontaneous bacterial peritonitis, (4) heart failure and stage 4 chronic kidney disease.

Design outcomes

Primary

Measure	Time frame
clinical benefits estimated 3 months later.	—

Countries

Japan

Contacts

Public ContactMasahiro Kikuchi

National Hospital Organization Tokyo Medical Center Department of Gastroenterology

kikuchim490611@yahoo.co.jp+81-3-3411-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026